Inpharmation Limited

POWER SEARCH PRICING

SOLUTIONS

inpharmation limited Company Information

Company Number

03567687

Next Accounts

Dec 2025

Directors

Karen Johnson

Gary Johnson

View All

Shareholders

gary anthony johnson

karen johnson

View All

Group Structure

View All

Industry

Business and domestic software development

Registered Address

evidence house, stokenchurch business park, stokenchurch, buckinghamshire, HP14 3FE

Website

www.inpharmation.com

inpharmation limited Estimated Valuation

£15.5m

Pomanda estimates the enterprise value of INPHARMATION LIMITED at £15.5m based on Net Assets of £6.5m and 2.38x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Inpharmation Limited is a live company located in stokenchurch, HP14 3FE with a Companies House number of 03567687. It operates in the business and domestic software development sector, SIC Code 62012. Founded in May 1998, it's largest shareholder is gary anthony johnson with a 41.9% stake. Inpharmation Limited is a mature, small sized company, Pomanda has estimated its turnover at £4.8m with rapid growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Inpharmation Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 2 areas for improvement. Company Health Check FAQs

Health Rating5out of 5

4 Strong

5 Regular

2 Weak

Size

annual sales of £4.8m, make it larger than the average company (£3.8m)

Growth

3 year (CAGR) sales growth of 44%, show it is growing at a faster rate (10.5%)

EXPORT

Inpharmation Limited's latest turnover from March 2024 is estimated at £4.8 million and the company has net assets of £6.5 million. According to their latest financial statements, Inpharmation Limited has 37 employees and maintains cash reserves of £4.3 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Turnover	4,832,410	3,664,418	3,449,593	1,628,988	2,984,642	1,951,406	2,583,245	1,266,212	433,711	1,259,121	1,275,618	1,011,413	1,259,764	602,778	656,156
Other Income Or Grants
Cost Of Sales	1,367,533	1,047,167	932,050	450,642	775,714	500,636	689,849	336,050	108,839	302,473	315,477	239,290	289,074	129,317	174,944
Gross Profit	3,464,877	2,617,251	2,517,543	1,178,345	2,208,928	1,450,771	1,893,395	930,163	324,872	956,648	960,141	772,122	970,691	473,461	481,212
Admin Expenses	3,277,956	1,240,001	4,000,611	2,023,201	-164,336	1,478,435	203,389	-44,845	-47,850	149,862	528,077	-149,921	825,777	323,555	-817,508
Operating Profit	186,921	1,377,250	-1,483,068	-844,856	2,373,264	-27,664	1,690,006	975,008	372,722	806,786	432,064	922,043	144,914	149,906	1,298,720
Interest Payable		472	311
Interest Receivable	227,135	157,021	29,387	5,009	4,116	29,200	21,800	8,844	14,641	12,172	9,823	6,311	3,842	4,219	2,098
Pre-Tax Profit	414,056	1,533,800	-1,453,992	-839,847	2,377,380	1,536	1,711,806	983,851	387,363	818,958	441,887	928,354	148,755	154,125	1,300,818
Tax	-103,514	-291,422			-451,702	-292	-325,243	-196,770	-77,472	-171,981	-101,634	-222,805	-38,676	-43,155	-364,229
Profit After Tax	310,542	1,242,378	-1,453,992	-839,847	1,925,678	1,244	1,386,563	787,081	309,890	646,977	340,253	705,549	110,079	110,970	936,589
Dividends Paid
Retained Profit	310,542	1,242,378	-1,453,992	-839,847	1,925,678	1,244	1,386,563	787,081	309,890	646,977	340,253	705,549	110,079	110,970	936,589
Employee Costs	2,503,360	2,425,014	2,132,912	1,692,830	1,542,502	1,691,372	1,472,141	1,194,532	269,931	642,706	648,101	522,900	677,757	302,218	342,967
Number Of Employees	37	37	35	30	27	28	25	21	5	12	12	10	13	6	7
EBITDA*	249,089	1,444,185	-1,414,702	-774,634	2,457,897	44,956	1,735,253	1,025,443	407,346	834,085	461,599	945,632	170,232	162,784	1,313,276

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Tangible Assets	1,979,735	2,041,595	2,092,906	2,164,756	2,220,303	2,585,762	784,191	467,673	480,890	431,078	425,091	415,988	430,983	411,695	43,882
Intangible Assets	12,188	12,188	12,188	12,188	12,188	12,188	12,188
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets	1,991,923	2,053,783	2,105,094	2,176,944	2,232,491	2,597,950	796,379	467,673	480,890	431,078	425,091	415,988	430,983	411,695	43,882
Stock & work in progress
Trade Debtors	968,188	694,937	665,944	156,526	672,607	272,402	458,991	104,601	71,990	219,417	209,991	161,654	226,725	101,721	113,949
Group Debtors
Misc Debtors	24,479	17,251	11,630	20,278	47,943	71,017	25,285	19,619	4,345
Cash	4,252,824	4,399,955	2,989,285	4,847,128	5,170,577	3,061,481	4,725,241	3,994,878	3,080,114	2,776,166	2,092,652	1,836,367	688,144	848,533	839,151
misc current assets
total current assets	5,245,491	5,112,143	3,666,859	5,023,932	5,891,127	3,404,900	5,209,517	4,119,098	3,156,449	2,995,583	2,302,643	1,998,021	914,869	950,254	953,100
total assets	7,237,414	7,165,926	5,771,953	7,200,876	8,123,618	6,002,850	6,005,896	4,586,771	3,637,339	3,426,661	2,727,734	2,414,009	1,345,852	1,361,949	996,982
Bank overdraft
Bank loan
Trade Creditors	44,895	21,374	15,271	1,468	49,153	48,837				568,868	519,229	545,744	183,552	314,290	59,185
Group/Directors Accounts	8,477	1,516
other short term finances			9,202
hp & lease commitments
other current liabilities	647,760	913,233	763,957	757,951	793,161	612,324	652,003	625,803	465,558
total current liabilities	701,132	936,123	788,430	759,419	842,314	661,161	652,003	625,803	465,558	568,868	519,229	545,744	183,552	314,290	59,185
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions	16,222	20,286	16,389	20,331	20,331	6,394	19,842	13,480	11,374	7,276	4,965	4,978	4,562		1,108
total long term liabilities	16,222	20,286	16,389	20,331	20,331	6,394	19,842	13,480	11,374	7,276	4,965	4,978	4,562		1,108
total liabilities	717,354	956,409	804,819	779,750	862,645	667,555	671,845	639,283	476,932	576,144	524,194	550,722	188,114	314,290	60,293
net assets	6,520,060	6,209,517	4,967,134	6,421,126	7,260,973	5,335,295	5,334,051	3,947,488	3,160,407	2,850,517	2,203,540	1,863,287	1,157,738	1,047,659	936,689
total shareholders funds	6,520,060	6,209,517	4,967,134	6,421,126	7,260,973	5,335,295	5,334,051	3,947,488	3,160,407	2,850,517	2,203,540	1,863,287	1,157,738	1,047,659	936,689

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Operating Activities
Operating Profit	186,921	1,377,250	-1,483,068	-844,856	2,373,264	-27,664	1,690,006	975,008	372,722	806,786	432,064	922,043	144,914	149,906	1,298,720
Depreciation	62,168	66,935	68,366	70,222	84,633	72,620	45,247	50,435	34,624	27,299	29,535	23,589	25,318	12,878	14,556
Amortisation
Tax	-103,514	-291,422			-451,702	-292	-325,243	-196,770	-77,472	-171,981	-101,634	-222,805	-38,676	-43,155	-364,229
Stock
Debtors	280,479	34,614	500,770	-543,746	377,131	-140,857	360,056	47,885	-143,082	9,426	48,337	-65,071	125,004	-12,228	113,949
Creditors	23,521	6,103	13,803	-47,685	316	48,837			-568,868	49,639	-26,515	362,192	-130,738	255,105	59,185
Accruals and Deferred Income	-265,473	149,276	6,006	-35,210	180,837	-39,679	26,200	160,245	465,558
Deferred Taxes & Provisions	-4,064	3,897	-3,942		13,937	-13,448	6,362	2,106	4,098	2,311	-13	416	4,562	-1,108	1,108
Cash flow from operations	-380,920	1,277,425	-1,899,605	-313,783	1,824,154	181,231	1,082,516	943,139	373,744	704,628	285,100	1,150,506	-119,624	385,854	895,391
Investing Activities
capital expenditure	-308	-15,624	3,484	-14,675	280,826	-1,874,191	-373,953	-37,218	-84,436	-33,286	-38,638	-8,594	-44,606	-380,691	-58,438
Change in Investments
cash flow from investments	-308	-15,624	3,484	-14,675	280,826	-1,874,191	-373,953	-37,218	-84,436	-33,286	-38,638	-8,594	-44,606	-380,691	-58,438
Financing Activities
Bank loans
Group/Directors Accounts	6,961	1,516
Other Short Term Loans		-9,202	9,202
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue	1	5													100
interest	227,135	156,549	29,076	5,009	4,116	29,200	21,800	8,844	14,641	12,172	9,823	6,311	3,842	4,219	2,098
cash flow from financing	234,097	148,868	38,278	5,009	4,116	29,200	21,800	8,844	14,641	12,172	9,823	6,311	3,842	4,219	2,198
cash and cash equivalents
cash	-147,131	1,410,670	-1,857,843	-323,449	2,109,096	-1,663,760	730,363	914,764	303,948	683,514	256,285	1,148,223	-160,389	9,382	839,151
overdraft
change in cash	-147,131	1,410,670	-1,857,843	-323,449	2,109,096	-1,663,760	730,363	914,764	303,948	683,514	256,285	1,148,223	-160,389	9,382	839,151

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for inpharmation limited. Get real-time insights into inpharmation limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for inpharmation limited by selecting its closest rivals, whether from the INFORMATION AND COMMUNICATION sector, other small companies, companies in HP14 area or any other competitors across 12 key performance metrics.

INPHARMATION LIMITED group structure

Inpharmation Limited has no subsidiary companies.

Ultimate parent company

INPHARMATION LIMITED

03567687

INPHARMATION LIMITED Shareholders

gary anthony johnson	41.9%
karen johnson	41.9%
robert graham watson	11.43%
samuel james johnson	2.86%
nicholas harold taylor	0.95%
kim hardy robinson	0.95%

Inpharmation Limited currently has 6 directors. The longest serving directors include Mrs Karen Johnson (May 1998) and Mr Gary Johnson (May 1998).

officer	country	age	start	end	role
Mrs Karen Johnson	England	66 years	May 1998	-	Director
Mr Gary Johnson	England	66 years	May 1998	-	Director
Mr Robert Watson	England	67 years	Apr 2003	-	Director
Mr Samuel Johnson	England	36 years	Jun 2021	-	Director
Mr Kim Robinson		36 years	Jun 2021	-	Director
Mr Nicholas Taylor	England	38 years	Jun 2021	-	Director

P&L

March 2024

turnover

4.8m

+32%

operating profit

186.9k

gross margin

71.8%

+0.39%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2024

net assets

6.5m

+0.05%

total assets

7.2m

+0.01%

cash

4.3m

-0.03%

net assets

Total assets minus all liabilities

Similar Companies

redzebra software limited

4.5

squared paper ltd

mission datalabs ltd

3.5

isatec limited

britfin technologies limited

company number

03567687

Type

Private limited with Share Capital

industry

62012 - Business and domestic software development

incorporation date

May 1998

ultimate parent company

None

previous names

N/A

address

evidence house, stokenchurch business park, stokenchurch, buckinghamshire, HP14 3FE

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to inpharmation limited.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for INPHARMATION LIMITED. This can take several minutes, an email will notify you when this has completed.

inpharmation limited Company Information

inpharmation limited Estimated Valuation

inpharmation limited Estimated Valuation

inpharmation limited Estimated Valuation

Inpharmation Limited Overview

Inpharmation Limited Health Check

INPHARMATION LIMITED financials

inpharmation limited Credit Report and Business Information

Inpharmation Limited Competitor Analysis

inpharmation limited Ownership

inpharmation limited directors

inpharmation limited company details

inpharmation limited Charges & Mortgages

inpharmation limited Capital Raised & Share Issues BETA

inpharmation limited Companies House Filings - See Documents